Eileen Smith

2.0k total citations
43 papers, 876 citations indexed

About

Eileen Smith is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Eileen Smith has authored 43 papers receiving a total of 876 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 18 papers in Hematology and 17 papers in Pathology and Forensic Medicine. Recurrent topics in Eileen Smith's work include Lymphoma Diagnosis and Treatment (16 papers), Hematopoietic Stem Cell Transplantation (11 papers) and Viral-associated cancers and disorders (7 papers). Eileen Smith is often cited by papers focused on Lymphoma Diagnosis and Treatment (16 papers), Hematopoietic Stem Cell Transplantation (11 papers) and Viral-associated cancers and disorders (7 papers). Eileen Smith collaborates with scholars based in United States and United Kingdom. Eileen Smith's co-authors include Anthony S. Stein, David S. Snyder, Pablo Parker, Stephen J. Forman, Joyce C. Niland, Auayporn Nademanee, G. Schmidt, Andrew Dagis, Neil Kogut and Margaret O’Donnell and has published in prestigious journals such as New England Journal of Medicine, Journal of the American Chemical Society and Journal of Clinical Oncology.

In The Last Decade

Eileen Smith

40 papers receiving 855 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eileen Smith United States	14	515	300	255	253	135	43	876
Neil Kogut United States	18	352 0.7×	495 1.6×	135 0.5×	349 1.4×	116 0.9×	52	914
Ni‐Chun Tsai United States	16	242 0.5×	382 1.3×	130 0.5×	321 1.3×	103 0.8×	48	712
Robert Witherspoon United States	13	488 0.9×	219 0.7×	229 0.9×	136 0.5×	144 1.1×	16	727
Pablo Parker United States	9	472 0.9×	286 1.0×	148 0.6×	132 0.5×	95 0.7×	10	741
A.-M. Stoppa France	14	537 1.0×	484 1.6×	133 0.5×	240 0.9×	130 1.0×	22	970
Deborah Marcellus United States	19	491 1.0×	555 1.9×	251 1.0×	495 2.0×	240 1.8×	30	1.2k
Vladan Vučinić Germany	18	518 1.0×	333 1.1×	230 0.9×	148 0.6×	153 1.1×	105	934
Marco Rabusin Italy	15	359 0.7×	125 0.4×	195 0.8×	168 0.7×	88 0.7×	43	818
Philip A. Stevenson United States	14	298 0.6×	199 0.7×	353 1.4×	102 0.4×	87 0.6×	45	733
Kinuko Tajima Japan	16	286 0.6×	532 1.8×	131 0.5×	131 0.5×	70 0.5×	51	906

Countries citing papers authored by Eileen Smith

Since Specialization

Citations

This map shows the geographic impact of Eileen Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eileen Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eileen Smith more than expected).

Fields of papers citing papers by Eileen Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eileen Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eileen Smith. The network helps show where Eileen Smith may publish in the future.

Co-authorship network of co-authors of Eileen Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Eileen Smith. A scholar is included among the top collaborators of Eileen Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eileen Smith. Eileen Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wong, Jeffrey Y.C., Amandeep Salhotra, Savita Dandapani, et al.. (2024). Phase II Trial of TMLI 20 Gy in Combination with Cyclophosphamide and Etoposide in Patients with Poor-Risk Acute Leukemia. International Journal of Radiation Oncology*Biology*Physics. 120(2). S90–S91.

Ma, Huiyan, Bernard Tegtmeier, Jana Dickter, et al.. (2024). Impact of Antifungal Prophylaxis Continuation or Discontinuation After Allogeneic Hematopoietic Cell Transplant on the Incidence of Invasive Mold Infection. Open Forum Infectious Diseases. 11(8). ofae409–ofae409.

Salhotra, Amandeep, Dongyun Yang, Sally Mokhtari, et al.. (2024). Phase 1 Trial Investigating the Safety and Tolerability of Leflunomide in Patients with Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD) after Allogeneic Hematopoietic Cell Transplant (alloHCT). Transplantation and Cellular Therapy. 30(2). S282–S283. 1 indexed citations

Wong, Jeffrey Y.C., Firoozeh Sahebi, Savita Dandapani, et al.. (2023). First-in-Human Phase I Trial Combining Biologically Guided Radioimmunotherapy (RIT) Using a 90Y-Anti-CD25 Monoclonal Antibody (Mab) with CT-guided Total Marrow and Lymphoid Irradiation (TMLI) in Relapsed and Refractory (R/R) Acute Leukemia. International Journal of Radiation Oncology*Biology*Physics. 117(2). S162–S162. 1 indexed citations

Aribi, Ahmed, Lihua E. Budde, Joseph Alvarnas, et al.. (2022). Durable Leukemia and HIV Remission without Antiviral Therapy Following an Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) Using a Donor with CCR5-Δ32/Δ32 Homozygosity for an Acute Myeloid Leukemia (AML) Patient. Blood. 140(Supplement 1). 7597–7598. 1 indexed citations

Ball, Brian, Shukaib Arslan, Paul Koller, et al.. (2021). Outcomes of Venetoclax and Hypomethylating Agents (HMA) in Adult Patients with KMT2A-Rearranged Leukemias. Blood. 138(Supplement 1). 3430–3430. 1 indexed citations

Mei, Matthew, Ni‐Chun Tsai, Sally Mokhtari, et al.. (2020). Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation. 26(8). 1425–1432. 3 indexed citations

Wagner, Jamie R., Mary C. Clark, Brenda Chang, et al.. (2020). Developing and Monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory Program. Biology of Blood and Marrow Transplantation. 26(8). 1386–1393. 9 indexed citations

Zain, Jasmine M., Jennifer Simpson, Joycelynne Palmer, et al.. (2020). Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients with Mature T-Cell NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen". Blood. 136(Supplement 1). 10–11. 1 indexed citations

10.

Smith, Eileen, Hongli Li, Jonathan W. Friedberg, et al.. (2017). Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). Biology of Blood and Marrow Transplantation. 24(4). 700–707. 11 indexed citations

11.

Fung, Henry C., Patrick J. Stiff, Jeff Schriber, et al.. (2007). Tandem Autologous Stem Cell Transplantation for Patients with Primary Refractory or Poor Risk Recurrent Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation. 13(5). 594–600. 37 indexed citations

12.

Rodríguez, Roberto, Auayporn Nademanee, Nora Ruel, et al.. (2006). Comparison of Reduced-Intensity and Conventional Myeloablative Regimens for Allogeneic Transplantation in Non-Hodgkin’s Lymphoma. Biology of Blood and Marrow Transplantation. 12(12). 1326–1334. 76 indexed citations

13.

Somlo, George, Warren Chow, Lucille Leong, et al.. (2001). Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies. Biology of Blood and Marrow Transplantation. 7(5). 284–293. 5 indexed citations

14.

Egan, Conleth A., et al.. (2001). Linear IgA bullous dermatosis responsive to a gluten-free diet. The American Journal of Gastroenterology. 96(6). 1927–1929. 14 indexed citations

15.

Strobl, Frank J., Karl V. Voelkerding, & Eileen Smith. (1999). Management of chronic myeloid leukemia during pregnancy with leukapheresis. Journal of Clinical Apheresis. 14(1). 42–44. 36 indexed citations

16.

Ross, Maureen, G. Schmidt, Joyce C. Niland, et al.. (1999). Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: Effect on chronic graft-vs.-host disease and long-term survival. Biology of Blood and Marrow Transplantation. 5(5). 285–291. 21 indexed citations

17.

Margolin, Kim, Koen van Besien, Christine L. Wright, et al.. (1999). Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma. Biology of Blood and Marrow Transplantation. 5(1). 36–45. 16 indexed citations

18.

Smith, Eileen, Irena Sniecinski, Andrew Dagis, et al.. (1998). Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host disease. Biology of Blood and Marrow Transplantation. 4(1). 27–37. 65 indexed citations

19.

Stein, Anthony S., Margaret O’Donnell, GM Schmidt, et al.. (1996). In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission.. Journal of Clinical Oncology. 14(8). 2206–2216. 46 indexed citations

20.

Chao, Nelson J., G. Schmidt, Joyce C. Niland, et al.. (1993). Cyclosporine, Methotrexate, and Prednisone Compared with Cyclosporine and Prednisone for Prophylaxis of Acute Graft-versus-Host Disease. New England Journal of Medicine. 329(17). 1225–1230. 211 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact